ReviewMolecular diagnosis & therapy2006
Genetic and epigenetic biomarkers in cancer : improving diagnosis, risk assessment, and disease stratification.
Review in Molecular diagnosis & therapy, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Radiation-Induced Normal Tissue Damage: Oxidative Stress and Epigenetic Mechanisms.Oxidative medicine and cellular longevity · 2019Review
- Anticancer Activity of Sulforaphane: The Epigenetic Mechanisms and the Nrf2 Signaling Pathway.Oxidative medicine and cellular longevity · 2018Review
- Epigenetic regulation of EFEMP1 in prostate cancer: biological relevance and clinical potential.Journal of cellular and molecular medicine · 2014Article
- Computational modeling and epidemiologic approaches: a new section of the Journal of Translational Medicine.Journal of translational medicine · 2012Article
- Cancer control and prevention by nutrition and epigenetic approaches.Antioxidants & redox signaling · 2012Review
- Epigenome-Wide Association Studies (EWAS) in Cancer.Current genomics · 2012Article
- Biomarkers in prostate cancer epidemiology.Cancers · 2011Article
- Pancreatic cancer biomarkers and their implication in cancer diagnosis and epidemiology.Cancers · 2010Article
- Microdevices integrating affinity columns and capillary electrophoresis for multibiomarker analysis in human serum.Lab on a chip · 2010Article
- Cancer biomarkers: are we ready for the prime time?Cancers · 2010Article
- Inactivation of FBXW7/hCDC4-β expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer.Breast cancer research : BCR · 2010Article
- Global epigenetic screening technologies: a novel tool to address cancer health disparities in high-risk population groups.Puerto Rico health sciences journal · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gene expression patterns change during the initiation, progression, and development of cancer, as a result of both genetic and epigenetic mechanisms. Genetic changes arise due to irreversible changes in the nucleotide sequence, whereas epigenetic changes occur due to changes in chromatin conformation, histone acetylation, and methylation of the CpG islands located primarily in the promoter region of a gene. Both genetic and epigenetic markers can potentially be utilized to identify different stages of tumor development. Several such markers exhibit high sensitivity and specificity for different tumor types and can be assayed in biofluids and other specimens collected by noninvasive technologies. In spite of the availability of large numbers of diagnostic markers, only a few have been clinically validated so far. The current status and the challenges in the field of genetic and epigenetic markers in cancer diagnosis, risk assessment, and disease stratification are discussed.
Indexed as
Identifiers
16646573What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.